| # | Drug | Count |
|---|---|---|
| 0 | ADALIMUMAB | 78 |
| 1 | TRASTUZUMAB | 75 |
| 2 | METHOTREXATE SODIUM | 60 |
| 3 | ETANERCEPT | 57 |
| 4 | INFLIXIMAB | 48 |
| 5 | PERTUZUMAB | 48 |
| 6 | CAPECITABINE | 47 |
| 7 | METHOTREXATE | 45 |
| 8 | ESTROGENS, CONJUGATED | 42 |
| 9 | CONJUGATED ESTROGENS | 41 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | FLOXURIDINE | 2 | 0.0116 |
| 1 | ADO-TRASTUZUMAB EMTANSINE | 36 | 0.0043 |
| 2 | BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE | 2 | 0.0032 |
| 3 | ACLIDINIUM BROMIDE | 14 | 0.0022 |
| 4 | MOMETASONE FUROATE MONOHYDRATE | 1 | 0.0020 |
| 5 | PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF | 9 | 0.0019 |
| 6 | PERTUZUMAB | 48 | 0.0017 |
| 7 | NERATINIB | 4 | 0.0017 |
| 8 | LAPATINIB | 26 | 0.0017 |
| 9 | TEBENTAFUSP | 1 | 0.0017 |
| # | Drug class | Count |
|---|---|---|
| 0 | Tumor Necrosis Factor Blocker [EPC] | 128 |
| 1 | HER2/neu Receptor Antagonist [EPC] | 90 |
| 2 | Aromatase Inhibitor [EPC] | 65 |
| 3 | Microtubule Inhibitor [EPC] | 60 |
| 4 | Corticosteroid [EPC] | 53 |
| 5 | Estrogen [EPC] | 53 |
| 6 | Nucleoside Metabolic Inhibitor [EPC] | 49 |
| 7 | Nonsteroidal Anti-inflammatory Drug [EPC] | 47 |
| 8 | Folate Analog Metabolic Inhibitor [EPC] | 46 |
| 9 | Benzodiazepine [EPC] | 43 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 17 | 0.0247 |
| 1 | Endoglycosidase [EPC] | 9 | 0.0049 |
| 2 | Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] | 1 | 0.0017 |
| 3 | Diagnostic Dye [EPC] | 1 | 0.0015 |
| 4 | HER2/neu Receptor Antagonist [EPC] | 90 | 0.0012 |
| 5 | Provitamin D2 Compound [EPC] | 29 | 0.0010 |
| 6 | Leptin Analog [EPC] | 1 | 0.0008 |
| 7 | Sphingosine 1-phosphate Receptor Modulator [EPC] | 8 | 0.0006 |
| 8 | Aromatase Inhibitor [EPC] | 65 | 0.0006 |
| 9 | Aryl Hydrocarbon Receptor Agonist [EPC] | 1 | 0.0005 |